Abstract
sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Animals
-
Clinical Trials, Phase I as Topic
-
Drug Evaluation, Preclinical
-
Humans
-
Mice
-
Neoplasms / blood supply
-
Neoplasms / therapy*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor Receptor-1 / metabolism
-
Vascular Endothelial Growth Factor Receptor-1 / therapeutic use*
-
Vascular Endothelial Growth Factor Receptor-2 / metabolism
-
Vascular Endothelial Growth Factor Receptor-2 / therapeutic use*
Substances
-
Angiogenesis Inhibitors
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factor Receptor-1
-
Vascular Endothelial Growth Factor Receptor-2